Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Interest Expenses (2016 - 2026)

Collegium Pharmaceutical has reported Interest Expenses over the past 9 years, most recently at $19.3 million for Q4 2025.

  • For Q4 2025, Interest Expenses fell 14.84% year-over-year to $19.3 million; the TTM value through Dec 2025 reached $82.3 million, up 11.27%, while the annual FY2025 figure was $82.3 million, 11.27% up from the prior year.
  • Interest Expenses for Q4 2025 was $19.3 million at Collegium Pharmaceutical, down from $21.8 million in the prior quarter.
  • Over five years, Interest Expenses peaked at $22.7 million in Q4 2024 and troughed at $4.8 million in Q4 2021.
  • A 5-year average of $16.2 million and a median of $19.2 million in 2022 define the central range for Interest Expenses.
  • Biggest five-year swings in Interest Expenses: plummeted 38.52% in 2021 and later skyrocketed 332.52% in 2022.
  • Year by year, Interest Expenses stood at $4.8 million in 2021, then soared by 332.52% to $20.6 million in 2022, then fell by 6.29% to $19.3 million in 2023, then grew by 17.49% to $22.7 million in 2024, then dropped by 14.84% to $19.3 million in 2025.
  • Business Quant data shows Interest Expenses for COLL at $19.3 million in Q4 2025, $21.8 million in Q3 2025, and $20.5 million in Q2 2025.